Antares Pharma (NASDAQ:ATRS) Issues Earnings Results

Antares Pharma (NASDAQ:ATRS) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.04) by $0.03, Bloomberg Earnings reports. Antares Pharma had a negative return on equity of 17.94% and a negative net margin of 7.91%. The firm had revenue of $28.43 million during the quarter, compared to the consensus estimate of $21.66 million. Antares Pharma updated its FY 2019 guidance to EPS.

Shares of NASDAQ ATRS traded up $0.01 on Wednesday, hitting $3.29. The company had a trading volume of 33,168 shares, compared to its average volume of 958,586. Antares Pharma has a 12-month low of $2.53 and a 12-month high of $3.96. The company has a 50 day moving average price of $3.16. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.28 and a quick ratio of 1.90. The firm has a market cap of $525.26 million, a price-to-earnings ratio of -82.25 and a beta of 0.95.

ATRS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $4.50 price target on shares of Antares Pharma in a research report on Monday, May 6th. BidaskClub raised Antares Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Antares Pharma currently has an average rating of “Buy” and an average target price of $4.83.

Several hedge funds and other institutional investors have recently modified their holdings of ATRS. Corrado Advisors LLC acquired a new stake in Antares Pharma during the second quarter valued at approximately $26,000. Alpine Woods Capital Investors LLC acquired a new stake in Antares Pharma during the first quarter valued at approximately $30,000. Aperio Group LLC acquired a new stake in Antares Pharma during the second quarter valued at approximately $47,000. Enterprise Bank & Trust Co acquired a new stake in Antares Pharma during the first quarter valued at approximately $45,000. Finally, Searle & CO. acquired a new stake in Antares Pharma during the first quarter valued at approximately $61,000. 43.05% of the stock is owned by institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Read More: What is a Fiduciary?

Earnings History for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.